TNFR-targeted agents in development
| TNF receptor molecule | Name | Description | Sponsor | Phase in cancer patients |
|---|---|---|---|---|
| 4-1BB (CD137) | CART19 cells | T cells transduced with antibody against CD19 linked to the intracellular signaling domains of 4-1BB and CD3-zeta | University of Pennsylvania and others | II |
| Urelumab | Fully human anti-CD137 agonist monoclonal antibody | Bristol Myers-Squibb | I | |
| OX40 | Mouse monoclonal anti-OX40 agonist antibody | Providence Health & Services and others | II | |
| Humanized antibody against OX40 | Preclinical | |||
| hFcILZOX40L | Recombinant human Fc:OX40L fusion protein | Providence Portland Medical Center | Preclinical | |
| GITR | TRX518 | Humanized anti-GITR agonist monoclonal antibody | GITR, Inc. | I |
| GITRL RNA DC | GITRL-expressing DCs | Duke University | I | |
| CD27 | CDX-1127 | Fully human anti-CD27 agonist monoclonal antibody | Celldex Therapeutics | I |
Abbreviation: DCs Dendritic Cells, GITR Glucocorticoid-Induced TNFR-Related Gene, GITRL GITR Ligand, TNF Tumor-Necrosis Factor, TNFR Tumor-Necrosis Factor Receptor.